Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates
The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.
Over-the-counter access to progestin-only oral contraceptives shows higher use among patients with prior pregnancies and those not receiving recent contraceptive counseling.
A recent study shows that even 3.4 minutes of vigorous intermittent lifestyle physical activity per day could significantly reduce cardiovascular risk, particularly in non-exercising women.
A recent study assessed the efficacy of Botulinum Toxin A injections in conjunction with pelvic floor muscle therapy for women with chronic pelvic pain, revealing interesting insights into its effectiveness compared to a placebo.
Recent study links tibolone use in menopausal hormone therapy to a 52% increased cardiovascular disease risk, emphasizing the need for tailored hormone therapy approaches and further research in BMJ.